The third annual RECOVER-Treating Long COVID (RECOVER-TLC) Workshop will be held November 4-5, 2026 in Bethesda, Maryland, with hybrid in-person and virtual attendance. Hosted by the National Institute of Allergy and Infectious Diseases and the Foundation for the National Institutes of Health, the workshop brings together researchers, clinicians, patient advocates, and people with Long COVID. Attendees will get updates on REVERSE-LC (baricitinib, currently enrolling) and the Tame-LC (semaglutide), Brave-LC (low-dose naltrexone), and Block-LC (stellate ganglion nerve block) trials preparing to launch, and will be asked for input on future research priorities.